These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

793 related items for PubMed ID: 10594855

  • 21. Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
    Qin W, Zhu W, Wagner-Mann C, Sauter ER.
    Ann Surg Oncol; 2003 Oct; 10(8):948-53. PubMed ID: 14527916
    [Abstract] [Full Text] [Related]

  • 22. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
    Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, Schildberg FW.
    J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
    [Abstract] [Full Text] [Related]

  • 23. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 24. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
    Andres SA, Edwards AB, Wittliff JL.
    J Clin Lab Anal; 2012 Feb; 26(2):93-103. PubMed ID: 22467324
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
    Nozaki S, Endo Y, Kawashiri S, Nakagawa K, Yamamoto E, Yonemura Y, Sasaki T.
    Oral Oncol; 1998 Jan; 34(1):58-62. PubMed ID: 9659521
    [Abstract] [Full Text] [Related]

  • 28. Plasminogen Activation System in Rectal Adenocarcinoma.
    Razik E, Kobierzycki C, Grzegrzolka J, Podhorska-Okolow M, Drag-Zalesinska M, Zabel M, Dziegiel P.
    Anticancer Res; 2015 Nov; 35(11):6009-15. PubMed ID: 26504024
    [Abstract] [Full Text] [Related]

  • 29. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
    Morii T, Yabe H, Morioka H, Yamada R, Nakagawa T, Toyama Y.
    Anticancer Res; 2000 Nov; 20(5A):3031-6. PubMed ID: 11062719
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
    Dublin E, Hanby A, Patel NK, Liebman R, Barnes D.
    Am J Pathol; 2000 Oct; 157(4):1219-27. PubMed ID: 11021826
    [Abstract] [Full Text] [Related]

  • 32. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma.
    Zhou L, Hayashi Y, Itoh T, Wang W, Rui J, Itoh H.
    Pathol Int; 2000 May; 50(5):392-7. PubMed ID: 10849328
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
    Buø L, Meling GI, Karlsrud TS, Johansen HT, Aasen AO.
    Hum Pathol; 1995 Oct; 26(10):1133-8. PubMed ID: 7557947
    [Abstract] [Full Text] [Related]

  • 37. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA, Leaper DJ, Hayter JP, Dickenson AJ.
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [Abstract] [Full Text] [Related]

  • 38. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
    Li P, Gao Y, Ji Z, Zhang X, Xu Q, Li G, Guo Z, Zheng B, Guo X.
    J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
    [Abstract] [Full Text] [Related]

  • 39. Serine proteinase activation in esophageal cancer.
    Tang WH, Friess H, Kekis PB, Martignoni ME, Fukuda A, Roggo A, Zimmerman A, Büchler MW.
    Anticancer Res; 2001 Oct; 21(4A):2249-58. PubMed ID: 11724279
    [Abstract] [Full Text] [Related]

  • 40. Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients.
    Horvatic Herceg G, Herceg D, Kralik M, Kulic A, Bence-Zigman Z, Tomic-Brzac H, Bracic I, Kusacic-Kuna S, Prgomet D.
    Otolaryngol Head Neck Surg; 2013 Oct; 149(4):533-40. PubMed ID: 23835563
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.